<DOC>
	<DOCNO>NCT01518569</DOCNO>
	<brief_summary>The purpose present study determine whether ulinastatin , urinary anti-trypsin inhibitor , attenuate cardiopulmonary bypass ( CPB ) -activated systemic inflammatory response cardiac surgery CPB . Serial measurement analysis several inflammatory cytokine ( bactericidal permeability increase protein , interleukin-6 , tumor necrosis factor-α ) well marker cardiac injury , renal impairment oxygenation profile perform determine ulinastatin 's efficacy .</brief_summary>
	<brief_title>Ulinastatin 's Anti-inflammatory Reaction Cardiac Surgery</brief_title>
	<detailed_description>Applying aortic cross-clamp ( ACC ) cardiopulmonary bypass ( CPB ) cardiac surgery produce variable systemic inflammatory reaction . As common complication reaction , pulmonary dysfunction , usually indicate postoperative hypoxemia , frequently associate cardiac surgery employ CPB use major predictor morbidity mortality . Circulating humoral cellular factor involve development systemic inflammatory reaction include organ dysfunction . So far , many study analyze concentration inflammatory marker ( cytokine ) determine degree systemic inflammatory response various condition . Ulinastatin anti-inflammatory activity suppress infiltration neutrophil . Previous study suggest ulinastatin 's cytoprotective effect ischemia-reperfusion injury major organ inhibition inflammatory marker production . The purpose present study determine ulinastatin 's possible protective efficacy attenuate CPB-activated systemic inflammatory response regard postoperative cardiac , renal pulmonary dysfunction cardiac surgery CPB . Serial measurement analysis several inflammatory cytokine , bactericidal permeability increase protein ( BPI ) , interleukin ( IL ) -6 , tumor necrosis factor ( TNF ) -α , well marker cardiac injury , renal impairment oxygenation profile , creatine kinase-MB ( CK-MB ) , troponin I ( TnI ) , C-reactive protein ( CRP ) , arterial O2 tension /inspired O2 fraction ( PaO2/FiO2 ratio ) , perform purpose .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Urinastatin</mesh_term>
	<criteria>elective cardiac surgery employ CPB urgent/emergency surgery , previous heart surgery , combine CABG valve surgery , age &gt; 75 yr , leave ventricular ejection fraction &lt; 0.45 , diabetes treat insulin , active gastropathic disorder , treatment chronic obstructive pulmonary disease , preoperative use steroid postoperative reoperation due bleed control pre postoperative renal replacement therapy leave ventricular assist device implantation</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>ulinastatin</keyword>
	<keyword>systemic inflammation</keyword>
	<keyword>cardiac surgery</keyword>
	<keyword>cardiopulmonary bypass</keyword>
</DOC>